ADVM - Adverum Biotechnologies, Inc.

4.36
0.100   2.294%

Share volume: 1,023,039
Last Updated: 12-08-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$4.26
0.10
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 35%
Dept financing 40%
Liquidity 49%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
-5.22%
1 Year
-5.42%
2 Year
-69.17%
Key data
Stock price
$4.36
P/E Ratio 
0.00
DAY RANGE
$4.23 - $4.38
EPS 
-$7.92
52 WEEK RANGE
$1.78 - $5.75
52 WEEK CHANGE
-$0.23
MARKET CAP 
95.058 M
YIELD 
N/A
SHARES OUTSTANDING 
22.077 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
1.60
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Laurent Fischer
Region: US
Website: adverum.com
Employees: 190
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Adverum Biotechnologies, Inc. develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Recent news